Myositis ossificans
MONDO:0003964A disorder characterized by non-neoplastic bone formation in soft tissues. It usually follows blunt trauma and bleeding in the deep soft tissues.
Also known as: FOP, myositis ossificans progressiva, progressive myositis ossificans, progressive ossifying myositis, fibrodysplasia ossificans progressiva
13 clinical trials for this condition and its sub-types, 11 tagged with Myositis ossificans itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Myositis ossificans
-
Traumatic myositis ossificans 0 trials
-
Hip replacement bleeding breakthrough: drug could cut transfusions
Disease control OngoingThis study tests whether tranexamic acid, a drug that helps blood clot, can reduce blood loss during planned hip replacement surgery. About 1000 adults having elective hip replacement will receive the drug directly into the joint during surgery. The goal is to see if it lowers th…
Sponsor: St. Anne's University Hospital Brno, Czech Republic • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a cancer drug stop the body from making extra bone?
Disease control OngoingThis phase 2 trial tests whether saracatinib, an oral drug originally developed for cancer, can prevent new abnormal bone growth in adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic condition where muscle and soft tissue turn into bone. Twenty adults with ac…
Phase 2 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Promising drug may halt extra bone formation in rare 'Stone Man' disease
Disease control OngoingThis study tests an experimental drug, garetosmab, in 63 adults with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. The goal is to see if the drug safely reduces new bone growth and painful flare-ups. Participants receive either t…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Rare bone disease patients get early access to experimental drug
Disease control Expanded access (paused)This program offers garetosmab to adults with fibrodysplasia ossificans progressiva (FOP) who finished the main OPTIMA study. The goal is to provide the drug before it is officially approved. Participants must meet specific health criteria to join.
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could this drug stop the body from turning muscle into bone?
Disease control OngoingThis study tests an experimental drug called andecaliximab in 92 children and adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic condition where soft tissues turn into bone. The goal is to see if the drug can safely reduce new bone growth and flare-ups. Parti…
Phase 2/3 • Sponsor: Ashibio Inc • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC